CN101642450A - New application of dicaffeoylquinic acid - Google Patents
New application of dicaffeoylquinic acid Download PDFInfo
- Publication number
- CN101642450A CN101642450A CN200910164179A CN200910164179A CN101642450A CN 101642450 A CN101642450 A CN 101642450A CN 200910164179 A CN200910164179 A CN 200910164179A CN 200910164179 A CN200910164179 A CN 200910164179A CN 101642450 A CN101642450 A CN 101642450A
- Authority
- CN
- China
- Prior art keywords
- dicaffeoylquinic acid
- acid
- dicaffeoylquinic
- medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229950009125 cynarine Drugs 0.000 title claims abstract description 47
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000004112 neuroprotection Effects 0.000 claims abstract description 3
- UFCLZKMFXSILNL-BKUKFAEQSA-N 3,4-di-O-caffeoylquinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O UFCLZKMFXSILNL-BKUKFAEQSA-N 0.000 claims description 24
- UFCLZKMFXSILNL-PSEXTPKNSA-N Isochlorogenic acid b Chemical compound O([C@@H]1C[C@@](O)(C[C@H]([C@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-PSEXTPKNSA-N 0.000 claims description 24
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 claims description 19
- YDDUMTOHNYZQPO-BBLPPJRLSA-N 1,3-di-O-caffeoylquinic acid Natural products O[C@@H]1C[C@@](C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc1ccc(O)c(O)c1)C(O)=O YDDUMTOHNYZQPO-BBLPPJRLSA-N 0.000 claims description 19
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 claims description 19
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 17
- UFCLZKMFXSILNL-AALYGJCLSA-N 3,4-Dicaffeoylquinic acid Natural products O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@](O)(C(=O)O)C[C@@H]1O)/C=C/c1cc(O)c(O)cc1 UFCLZKMFXSILNL-AALYGJCLSA-N 0.000 claims description 14
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 claims description 12
- MVCIFQBXXSMTQD-UHFFFAOYSA-N 3,5-dicaffeoylquinic acid Natural products Cc1ccc(C=CC(=O)OC2CC(O)(CC(OC(=O)C=Cc3ccc(O)c(O)c3)C2O)C(=O)O)cc1C MVCIFQBXXSMTQD-UHFFFAOYSA-N 0.000 claims description 12
- 206010008118 cerebral infarction Diseases 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- UFCLZKMFXSILNL-BBLPPJRLSA-N (-) 4,5-dicaffeoylquinic acid Natural products OC=1C=C(C=CC=1O)C=CC(=O)O[C@@H]1C[C@@](C[C@H]([C@H]1OC(C=CC1=CC(=C(C=C1)O)O)=O)O)(C(=O)O)O UFCLZKMFXSILNL-BBLPPJRLSA-N 0.000 claims description 10
- UFCLZKMFXSILNL-UHFFFAOYSA-N NSC 649410 Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC1C(O)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-UHFFFAOYSA-N 0.000 claims description 10
- 210000003792 cranial nerve Anatomy 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 230000002490 cerebral effect Effects 0.000 claims description 3
- DWVBTGTYJNNGSW-MMNCBLCDSA-N C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O.C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O Chemical compound C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O.C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O DWVBTGTYJNNGSW-MMNCBLCDSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 abstract description 12
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 10
- 210000004556 brain Anatomy 0.000 abstract description 7
- 210000003710 cerebral cortex Anatomy 0.000 abstract description 7
- 230000004083 survival effect Effects 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 6
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 3
- 208000032382 Ischaemic stroke Diseases 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 210000002569 neuron Anatomy 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 241001013934 Erigeron breviscapus Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000005056 cell body Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000009738 saturating Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- -1 acyl quininic acid derivative Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- XXLFLUJXWKXUGS-UHFFFAOYSA-N 6-methoxyquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(OC)=CC=C21 XXLFLUJXWKXUGS-UHFFFAOYSA-N 0.000 description 2
- 241000157855 Cinchona Species 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000086346 Arnica chamissonis Species 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 206010004954 Birth trauma Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000019743 Cranial nerve injury Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011208 chromatographic data Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical class C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930190376 scutellarin Natural products 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了二咖啡酰奎宁酸在制备脑神经保护剂的药物中的用途，该药物可用于治疗缺血性中风。本发明还提供了一种脑神经保护剂的药物组合物。药效试验研究表明，二咖啡酰奎宁酸类成分是新的一类具有较好脑神经保护的有效成分，具有促进体外大脑皮层神经细胞存活和抗氧化作用，且具有一定透过血脑屏障能力。The invention provides the use of dicaffeoylquinic acid in the preparation of a medicine for protecting brain neurons, and the medicine can be used for treating ischemic stroke. The invention also provides a pharmaceutical composition of the brain neuroprotectant. Pharmacodynamic studies have shown that dicaffeoylquinic acid components are a new class of active ingredients with better brain neuroprotection, can promote the survival of cerebral cortex nerve cells in vitro and anti-oxidation, and have a certain ability to penetrate the blood-brain barrier ability.
Description
Technical field
The present invention relates to the new purposes of dicaffeoylquinic acid, particularly, is the purposes in the protectant medicine of preparation cranial nerve, belongs to field of medicaments.
Background technology
Apoplexy has another name called apoplexy, be with unexpected confused servant, hemiplegia, crooked mouth and tongue, speech not smoothgoing puckery or in silence, hemianesthesia is primary symptom, and have onset anxious, change fast characteristics, good sending out in a kind of disease of person in middle and old age, be the common frdquently encountered disease of middle-aged and elderly people, human existence and health in serious threat.Primary disease is equivalent to ischemic cerebrovascular (the Ischemic Cerebral vascular Disease of western medicine, ICVD), also claim Ischemic Stroke, have higher case fatality rate and disability rate, human beings'health and life security (Rao Mingli in serious threat, woods generation and. cerebrovascular disease. People's Health Publisher, 2002.172).As a kind of commonly encountered diseases, frequently-occurring disease, ICVD especially the limitation cerebral infarction with three big diseases that cause death of heart disease, malignant tumor majority state arranged side by side.Epidemiological study finds, China belong to one of this disease hotspot (Chen Jie. the epidemiology of cerebral infarction. practical cardio-cerebral-pulmo angiopathy magazine .2000,8 (3): 179～181).Motherland's medical science thinks, its sick position of apoplexy is at brain, and is closely related with the heart, kidney,liver,spleen, is the card of deficiency in origin and excess in superficiality, the etiology and pathogenesis complexity, and deficiency in origin is deficiency of the liver and kindey, deficiency of vital energy insufficiency of blood; Mark is real to be liver-wind stirring up internally, fire and wind stirring up each other, and burning hot interior strongly fragrant, the phlegm-damp heap soil or fertilizer over and around the roots is contained, and finally causes the internal resistance of the expectorant stasis of blood, and with the mechanism of qi superinverse, upset empties, and hoodwinks key clearly, becomes excess in the upper and deficiency in the lower, the critical syndrome that negative and positive are not maintained mutually.The symptom of its suddenly confused servant's syncope can be included the category that key closes coma in again.According to statistics, in the syndrome-classification of apoplexy, syndrome of blood stasis is taken the status as the leading factor, account for more than 73% of apoplexy (Tao Genyu, Du Xiaoquan. the status [J] of benefiting QI for activating blood circulation method in the cerebral infarction disease. ShanXi Chinese Medicine Academy journal, 1998,21 (3): 1).Though the pathogenesis of cerebral infarction is complicated, to sum up to get up, principal contradiction is stagnation of blood stasis.Over nearly 10 years, in, doctor trained in Western medicine bound pair stasis cerebral infarction carried out deep clinical and experimentation, the curative effect of stasis cerebral infarction disease obtains certainly substantially, its clinical report is also more.
Li Zusheng, dicaffeoylquinic acid (dicaffeoylquinic acids, DCQ) pharmacological experiment study progress, 2004 the 10th the 4th phases of volume of medical science summary, reported, reported the dicaffeoylquinic acid caffeic acid (caffeic acid) that to be a class do not waited by quininic acid (quinc acid) and number by the phenolic acids natural component that esterification comprehensively forms, extensively be present in the fruit trees such as Chinese medicine such as plant kingdom such as Flos Lonicerae, Flos Inulae, Herba Xanthii and Folium Camelliae sinensis, Fructus Crataegi.All multiactions such as the antioxidation of present report DCQ, antiinflammatory, antiviral, fibrosis, inhibition smooth muscle contraction, blood fat reducing.As number of patent application: 99105113.0, denomination of invention: 1, the preparation method of 5-two-O-coffeic acyl quininic acid derivative discloses 1, the preparation method of 5-two-O-coffeic acyl quininic acid derivative; Application number: 03141616.0, denomination of invention: breviscapine and dicaffeoylquinic acid drug regimen and application thereof disclose effective site breviscapine and dicaffeoylquinic acid combination and the new purposes in the acute and chronic hepatopathy of treatment thereof extracted in the Herba Erigerontis; Application number: 03117754.9, denomination of invention: erigeron breviscapus and preparation method thereof and the application in pharmacy disclose preparation method and the application in treatment cardiovascular and cerebrovascular disease, senile dementia disease, the high fat disease of control medicinal that erigeron breviscapus effective site comprises scutellarin and dicaffeoylquinic acid.Application number: 96101141.6, denomination of invention: the application of di-caffee acyl-oxy-quininic acid in pharmacy discloses 3,4-dicaffeoylquinic acid, 3, the application in cardiovascular and cerebrovascular disease of the preparation of 5-dicaffeoylquinic acid and drug regimen.Application number: 03117753, denomination of invention: Erigeroster B and preparation method thereof and the application in pharmacy disclose new caffeic acid ester compounds Erigeroster B, extraction separation method and conduct treatment cardiovascular and cerebrovascular diseases medicament.
Still do not have the report dicaffeoylquinic acid at present and be used for the protectant purposes of cranial nerve; also not with 1; 5-dicaffeoylquinic acid, 4; 5-dicaffeoylquinic acid, 3; 4-dicaffeoylquinic acid, 3, dicaffeoylquinic acids such as 5-dicaffeoylquinic acid be raw material separately or the relevant report of drug combination.
Summary of the invention
Technical scheme of the present invention has provided the new purposes of dicaffeoylquinic acid, particularly, is the purposes in the protectant medicine of preparation cranial nerve.The present invention also provides a kind of cranial nerve protective agent pharmaceutical composition.
The invention provides the purposes of dicaffeoylquinic acid in the protectant medicine of preparation cranial nerve.
Wherein, described medicine is the medicine of treatment cerebral infarction.
Wherein, described dicaffeoylquinic acid is 1,5-dicaffeoylquinic acid, 4, and 5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3, the 5-dicaffeoylquinic acid,
Structure is as follows:
1, the 5-dicaffeoylquinic acid
4,5-dicaffeoylquinic acid 3,4-dicaffeoylquinic acid
3, the 5-dicaffeoylquinic acid.
The invention provides a kind of drug composite of cerebral neuroprotection; it is by 1; 5-dicaffeoylquinic acid, 4; 5-dicaffeoylquinic acid, 3; 4-dicaffeoylquinic acid, 3; in the 5-dicaffeoylquinic acid a kind of its more than one be mixed into active component, add the medicament that acceptable accessories or adjuvant composition are prepared from.
Further preferably, it is by 1,5-dicaffeoylquinic acid, 4, and 5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3, the medicament that the 5-dicaffeoylquinic acid is prepared from for the active component compatibility, its weight proportion is:
1,5-dicaffeoylquinic acid 1-10 part, 4,5-dicaffeoylquinic acid 1-10 part, 3,4-dicaffeoylquinic acid 1-10 part, 3,5-dicaffeoylquinic acid 1-10 part.
Wherein, described 1,5-dicaffeoylquinic acid and 3, the 4-dicaffeoylquinic acid derives from Herba Erigerontis Erigeron breviscapus (Vant.) Hand.-Mazz. medical material, concrete extraction separation method is with 95% ethanol 60L, 70% ethanol 20L ethanol percolation, and vacuum decompression reclaims ethanol.Ethyl acetate layer extractum, normal pressure silica gel column chromatography and anti-phase C18 column chromatography purification repeatedly can obtain 1,5-dicaffeoylquinic acid and 3,4-dicaffeoylquinic acid.
Four chemical compounds of the present invention are known chemical compound; can extract by following document (I.Merfort.Caffeoylquinicacids from flowers of arnica Montana and arnicachamissonis[J] .Phytochemistry; 1992; 31 (6): 2111.H.Morshita.Chromatographic separation and identification of naturally occurringchlorogenic acids by ' Hnuclearmagnetic resonacespec-troscopy andmasss pectrometry[J] .Chromatography; 1984; 315:253.BarbaranTimmermann; Joseph Hoffmann.Constituents of chrysothamnuspaniculatus3:3; 4; 5-tricaffeoylquinicacid and 3; 4;-3; 5-and4; 5-dicaffeoylquinicacids[J] .J.Nat.Prod; 1983; 46 (3): 578. Teng Rong are big; Deng. spend the caffeoyl quinic acid composition in the Radix Morinae Bulleyanae in vain. the Wave Spectrum magazine; 2002,19 (2): 167 ~ 174)
Wherein, described preparation is: injection, drop pill or aerosol.
The present invention also provides pharmaceutical composition making the purposes for the treatment of in the medicine that is equipped with cerebral infarction.
A kind of pharmaceutical composition for the treatment of cerebral infarction provided by the invention can be realized: 1, extract each chemical compound from Herba Erigerontis, add the preparation that acceptable accessories or complementary composition are prepared from then by following technical solution.2, also can adopt the dicaffeoylquinic acid of commercially available or plant origin is raw material, adds the preparation that acceptable accessories or complementary composition are prepared from then.
Said medicine combination of the present invention can also can be extracted or preparation according to existing bibliographical information method available from commercially available commodity raw material.
The present invention also provides the application of this pharmaceutical composition in the medicine of the Cranial nerve injury as birth trauma of preparation treatment ischemic apoplexy sequelae, cerebrovascular disease.
Experimentation shows that the di-coffee mesitoyl quinine acid composition is the effective ingredient that a class has better cranial nerve protection, has to promote external cerebral cortex neurocyte survival and antioxidation, and has certain blood brain barrier ability that sees through; It is clear and definite to be used for the treatment of the cerebral infarction drug effect, provides a kind of new selection for clinical.
Obviously, according to foregoing of the present invention,,, can also make modification, replacement or the change of other various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.
The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
The specific embodiment
The preparation of embodiment 1 The compounds of this invention
Herba Erigerontis Erigeron breviscapus (Vant.) Hand.-Mazz. medical material (roguing grass) is used 95% ethanol 60L respectively, 70% ethanol 20L ethanol percolation, and vacuum decompression reclaims ethanol.Ethyl acetate layer extractum, normal pressure silica gel column chromatography and anti-phase C18 column chromatography purification repeatedly can obtain 1,5-dicaffeoylquinic acid and 3,4-dicaffeoylquinic acid.
Four kinds of chemical compounds of the present invention also can derive from commercially available kind, as 1,5-dicaffeoylquinic acid (the source bio tech ltd of middle mountain health), 4,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid (Shijiazhuang Yan Feng Pharmaceutical Technology Co., Ltd), 3, the self-control of 4-dicaffeoylquinic acid, purity is greater than 95%.
The preparation of embodiment 2 medicaments injections of the present invention
Get 1,5-dicaffeoylquinic acid 5g, 4,5-dicaffeoylquinic acid 5g, 3,4-dicaffeoylquinic acid 5g, 3,5-dicaffeoylquinic acid 5g, sodium chloride 85g, sodium sulfite 2g, add the dissolving of injection water, make 10000ml, be distributed into the injection that 3mg/2ml/ props up, intermediate detects, embedding, sterilization, labeling.
The preparation of embodiment 3 medicaments injections of the present invention
Get 1,5-dicaffeoylquinic acid 5g, 4,5-dicaffeoylquinic acid 50g, 3,4-dicaffeoylquinic acid 50g, 3,5-dicaffeoylquinic acid 50g, sodium chloride 85g, sodium sulfite 2g, add the dissolving of injection water, make 10000ml, be distributed into the injection that 3mg/2ml/ props up, intermediate detects, embedding, sterilization, labeling.
The preparation of embodiment 4 medicaments injections of the present invention
Get 1,5-dicaffeoylquinic acid 50g, 4,5-dicaffeoylquinic acid 5g, 3,4-dicaffeoylquinic acid 5g, 3,5-dicaffeoylquinic acid 5g, sodium chloride 85g, sodium sulfite 2g, add the dissolving of injection water, make 10000ml, be distributed into the injection that 3mg/2ml/ props up, intermediate detects, embedding, sterilization, labeling.
Below further prove beneficial effect of the present invention by pharmacodynamics test.
Test example 1 The compounds of this invention is to the influence of In vitro culture cerebral cortex neurocyte survival
The present invention discloses 1,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3, the drug efficacy study result of 5-dicaffeoylquinic acid.
Bed board: get 96 orifice plates, every hole adds 0.1mgmL-1 poly-D-lysine 50 μ L, and vibration is even, and the room temperature standing over night is standby.
Preparation cell suspension: the disconnected neck of neonatal rat is put to death, 75% alcohol-pickled sterilization, aseptic condition separates brain cortical tissue, removes the cerebrovascular film as far as possible, inserts in the ice Hanks liquid rinsing 3 times.Obtaining tissue is cut into the 1mm3 piece of tissue, and the trypsin with 0.25%+37 ℃ of digestion down of 0.05%II Collagen Type VI enzyme adds culture fluid and stops digestion behind the 30min, filter with 75 μ m cell screen clothes.With the centrifugal 8min of filtrate 1000rmin-1, abandon supernatant.Add complete culture solution (900mLL
-1The DMEM high glucose medium, 100mLL
-1Hyclone, L-glutaminate 0.45gL
-1, NaHCO3 3gL-1, HEPES 4.5gL-1, penicillin 1 * 105UL
-1, streptomycin 1 * 105UL
-1), suction pipe piping and druming makes it to be uniformly dispersed and makes single cell suspension.Liquid measure is cultivated in counting and adjustment makes every mL contain 1 * 106 cell.
Inoculated and cultured and medicine adding method: with cell suspension inoculation in through the bag quilt 96 orifice plates in, every hole 100 μ L change liquid after cultivating 24h, add cytosine arabinoside behind the 72h to suppress non-nerve growth, later every 2d half amount is changed liquid, 7d changes behind the liquid according to requirement of experiment, and what add various mass concentration gradients respectively respectively is subjected to reagent thing (establishing 5 dosage groups, by a certain percentage dilution), cumulative volume 200 μ L in every hole add culture fluid simultaneously and continue to cultivate as the blank group.
The MTT trace is colorimetry automatically: after adding drug effect 1d, every hole adds MTT liquid (tetramethyl azo azoles salt, 5mgmL
-1), after continuing to cultivate 4h, remove supernatant, PBS liquid rinsing 2 times, every hole adds dimethyl sulfoxide (DMSO) 150 μ L, fully vibration, room temperature leaves standstill 10min, measures absorption value in 492nm wavelength place with microplate reader.
The result shows that above chemical compound all has the effect that promotes external cerebral cortex neurocyte survival preferably.The results are shown in Table 1 ~ 3.
Table 13,5-DCQ and 1,5-DCQ is to the influence of In vitro culture cerebral cortex neurocyte survival
Table 2 erigeron breviscapus effective component is to the influence of In vitro culture cerebral cortex neurocyte survival
Table 33,4-DCQ is to the influence of In vitro culture cerebral cortex neurocyte survival
1,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 3, the saturating blood brain barrier result of study of 4-dicaffeoylquinic acid, the result shows 1,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 3, the 4-dicaffeoylquinic acid can see through external blood brain barrier model in various degree.The result of study of comprehensive above cranial nerve protection, 1,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 3,4-two caffeoyl quinines can see through the protective effect of blood brain barrier performance cranial nerve.
Test example 2 external blood brain barrier modelling and saturating blood brain barrier
Because the existence of blood brain barrier, nearly all macromolecular drug and 98% small-molecule drug all can not enter brain and central nervous system, and medicine can cross over blood brain barrier and reach effective treatment concentration be vital.For seeking and further analyze the effective substance of Herba Erigerontis brain targeting neuroprotective, this experiment employing brain micro blood vessel endothelium cell of former generation and star spongiocyte co-culture model analog in vitro BBB.Use efficient liquid phase chromatographic analysis, different time points is measured the transmitance of The compounds of this invention in 8h.
1, material and instrument
Day island proper Tianjin LC-10A high performance liquid chromatograph, the SPD-10AV UV-detector; The SCL-10A system controller; The CBL calorstat, N2000 chromatographic data work station.Nitrogen evaporator (KL-512, Beijing Kang Lin science and technology limited Company): high speed centrifuge (centrifuge 5417c, eppendorf company): ultrasonic washing instrument (AS10200, Tianjin Ao Tesaiensi Instr Ltd.)
Methanol, acetonitrile (Fisher company, chromatographically pure), the described chemical compound of the method for embodiment 1: 1,5-dicaffeoylquinic acid (the source bio tech ltd of middle mountain health), 4,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid (Shijiazhuang Yan Feng Pharmaceutical Technology Co., Ltd), 3, the self-control of 4-dicaffeoylquinic acid, purity is greater than 95%.
2, method and result
2.1 sample preparation
Select leak test to test male hole and carry out the permeability experiment, to adding 1,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid (0.2mgmL in the pond
-1) be subjected to add in the pond 600 μ L AC culture fluid.From be subjected to the pond, carefully collected filtrate each 100 μ L, 50 μ L, 50 μ L, 50 μ L, 50 μ L respectively in-20 ℃ of preservations at the 0th, 1,2,4,8 hour, treat to do sample treatment after all samplings finish.Wherein 0 hour is blank, to being the initial concentration (referring to Fig. 5-1) for the pond for the medicinal liquid that adds in the pond.Each sample nitrogen is dried up (37 ℃), respectively to wherein adding methanol, supersound process 20min, it is centrifugal that (5000rmin-1 * 10min), get supernatant makes HPLC and analyzes need testing solution.
2.2HPLC analyze
Chromatographic condition: Tianjin, island LC-10A high performance liquid chromatograph; Chromatographic column: be the octadecylsilane chemically bonded silica post, Yi Lite SinoChrom ODS-BP 5 μ m (250 * 4.6mm) posts number: E1817666, flow velocity: 1mLmin
-1Column temperature: room temperature;
3,5-dicaffeoylquinic acid mobile phase is acetonitrile: 0.6% formic acid (20: 80).The detection wavelength is 330nm.
The accurate respectively 20 μ L need testing solutions injection high performance liquid chromatograph of drawing detects.
2.3 transmitance is calculated
According to the HPLC measurement result, get following formula and calculate transmitance.
A wherein
Be subjected to the pondFor being subjected to the peak area of pond sample, A
For the pondFor supplying pond peak area, V
Be subjected to the pondFor being subjected to cell body to amass V
For the pondFor long-pending for cell body.Result of calculation sees Table 4.
The saturating external BBBM composition transmitance of table 4
Tab.4The?permeability?of?compounds?on?the?in?vitro?BBB?model
| Numbering | Chemical compound | For the pond peak area | For cell body long-pending (μ l) | 8h is subjected to the pond peak area | Be subjected to cell body to amass (μ l) | Transmitance (%) |
| ??1 | ??3，5-DCQ | ??256813.7 | ??300 | ??101640 | ??600 | ??79.15 |
| ??2 | ??1，5-DCQ | ??30541 | ??300 | ??8072.6 | ??650 | ??57.27 |
| ??3 | ??3，4-DCQ | ??35615 | ??300 | ??4692 | ??650 | ??28.54 |
| ??4 | ??4，5-DCQ | ??257202 | ??300 | ??27521 | ??650 | ??23.18 |
Above-mentioned test shows, 4, and 5-DCQ, 1,5-DCQ, 3,5-DCQ, 3,4-DCQ all can see through BBBM.Wherein 3,5-DCQ sees through the best results of BBBM.Above-mentioned evidence, four chemical compounds of the present invention all are cranial nerve protection effective ingredient of new saturating blood brain barrier.
Claims (7)
1, the purposes of dicaffeoylquinic acid in the protectant medicine of preparation cranial nerve.
2, purposes according to claim 1 is characterized in that: described medicine is the medicine of treatment cerebral infarction.
3, purposes according to claim 1 is characterized in that: described dicaffeoylquinic acid is 1,5-dicaffeoylquinic acid, 4, and 5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid or 3, the 5-dicaffeoylquinic acid,
Structure is as follows:
1, the 5-dicaffeoylquinic acid
4,5-dicaffeoylquinic acid 3,4-dicaffeoylquinic acid
3, the 5-dicaffeoylquinic acid.
4, a kind of drug composite of cerebral neuroprotection; it is characterized in that: it is by 1; 5-dicaffeoylquinic acid, 4; 5-dicaffeoylquinic acid, 3; 4-dicaffeoylquinic acid, 3; the mixture of one or more in the 5-dicaffeoylquinic acid is an active component, adds the medicament that acceptable accessories or adjuvant composition are prepared from.
5, pharmaceutical composition according to claim 4 is characterized in that: it is by 1,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3, the medicament that the 5-dicaffeoylquinic acid is prepared from for the active component compatibility, its weight proportion is:
1,5-dicaffeoylquinic acid 1-10 part, 4,5-dicaffeoylquinic acid 1-10 part, 3,4-dicaffeoylquinic acid 1-10 part, 3,5-dicaffeoylquinic acid 1-10 part.
6, according to any described pharmaceutical composition of claim 4-5, it is characterized in that: described preparation is: injection, drop pill or aerosol.
7, the purposes of any described pharmaceutical composition of claim 4-5 in the medicine of preparation treatment cerebral infarction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101641793A CN101642450B (en) | 2008-08-06 | 2009-08-04 | Pharmaceutical uses of dicaffeoylquinic acid |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810045740 | 2008-08-06 | ||
| CN200810045740.1 | 2008-08-06 | ||
| CN2009101641793A CN101642450B (en) | 2008-08-06 | 2009-08-04 | Pharmaceutical uses of dicaffeoylquinic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101642450A true CN101642450A (en) | 2010-02-10 |
| CN101642450B CN101642450B (en) | 2011-10-05 |
Family
ID=41654610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101641793A Expired - Fee Related CN101642450B (en) | 2008-08-06 | 2009-08-04 | Pharmaceutical uses of dicaffeoylquinic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101642450B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266318A (en) * | 2011-05-23 | 2011-12-07 | 中国人民解放军第二军医大学 | Application of caffeoylquinic acid and derivatives thereof in preparing anticomplementary medicines |
| CN103553922A (en) * | 2013-11-06 | 2014-02-05 | 天津科技大学 | Preparation of macranthoin G in eucommia ulmoides, and application of macranthoin G in neuroprotective medicine |
| CN104434896A (en) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | Application of dicaffeoylquinic acid derivative for preparing chemokine receptor 2b antagonist |
| CN108658843A (en) * | 2017-03-30 | 2018-10-16 | 上海医药工业研究院 | Acetobenzylamide piperidine amides analog derivative and its application as neuroprotection agent |
| CN108949743A (en) * | 2018-06-15 | 2018-12-07 | 翁炳焕 | A kind of full-length genome hybridizing clones method |
| CN109674777A (en) * | 2019-01-16 | 2019-04-26 | 中国科学院成都生物研究所 | Application of the isochlorogenic acid class compound in preparation neurodegenerative disease and hypochondriacal drug |
| EP4487845A4 (en) * | 2022-03-03 | 2025-02-19 | Seoul Nat Univ Hospital | COMPOSITION FOR THE PREVENTION, RELIEF OR TREATMENT OF DRY EYE OR MEIBOMIAN GLAND DYSFUNCTION |
-
2009
- 2009-08-04 CN CN2009101641793A patent/CN101642450B/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266318A (en) * | 2011-05-23 | 2011-12-07 | 中国人民解放军第二军医大学 | Application of caffeoylquinic acid and derivatives thereof in preparing anticomplementary medicines |
| CN104434896A (en) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | Application of dicaffeoylquinic acid derivative for preparing chemokine receptor 2b antagonist |
| CN103553922A (en) * | 2013-11-06 | 2014-02-05 | 天津科技大学 | Preparation of macranthoin G in eucommia ulmoides, and application of macranthoin G in neuroprotective medicine |
| CN108658843A (en) * | 2017-03-30 | 2018-10-16 | 上海医药工业研究院 | Acetobenzylamide piperidine amides analog derivative and its application as neuroprotection agent |
| CN108658843B (en) * | 2017-03-30 | 2021-06-04 | 上海医药工业研究院 | Acetylbenzylamine piperidine amide derivative and application thereof as cerebral nerve protective agent |
| CN108949743A (en) * | 2018-06-15 | 2018-12-07 | 翁炳焕 | A kind of full-length genome hybridizing clones method |
| CN109674777A (en) * | 2019-01-16 | 2019-04-26 | 中国科学院成都生物研究所 | Application of the isochlorogenic acid class compound in preparation neurodegenerative disease and hypochondriacal drug |
| EP4487845A4 (en) * | 2022-03-03 | 2025-02-19 | Seoul Nat Univ Hospital | COMPOSITION FOR THE PREVENTION, RELIEF OR TREATMENT OF DRY EYE OR MEIBOMIAN GLAND DYSFUNCTION |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101642450B (en) | 2011-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101642450A (en) | New application of dicaffeoylquinic acid | |
| US9687516B2 (en) | Preparation method for extractive of jinxuan hemorrhoid washing powder botanicals | |
| CN103316096A (en) | General flavone extract of seeds of nigella damascena l., nigella sativa l. or nigella glandulifera freyn et sint., and preparation method and use thereof | |
| CN105153084A (en) | Novel diterpene compound as well as preparation method and medicinal application thereof | |
| CN115154476B (en) | Extracts of Qingqian Liu and their anti-gout and uric acid-lowering applications | |
| CN101966172B (en) | New purpose of caffeic acid and derivatives thereof | |
| CN115304653A (en) | Four iridoid glycoside compounds extracted from dogwood, preparation method and application thereof | |
| Li | Chinese herbal medicine | |
| CN102357180B (en) | Traditional Chinese medicine composite for curing cancer and preparation method and application thereof | |
| CN102898322B (en) | Compound and preparation method and application thereof | |
| CN102178725B (en) | Total saponins of osmanthus chrysanthemum and its preparation method and medicinal use | |
| CN101559066A (en) | Application of 2'-O-beta-L-galactopyranosyl orientin and composition in preparing medicaments for resisting myocardial ischemia | |
| CN101606991A (en) | Preparation technology of Fuguigutong Compound by Microbial Fermentation | |
| CN101948453A (en) | Novel NEO-clerodane typed diterpene compound and application thereof | |
| CN101077873B (en) | Novel NEO-clerodane type diterpene compound and application thereof | |
| CN1923241B (en) | Pharmaceutical composition comprising epimedium extract, uncaria extract, gastrodin and its preparation method and application | |
| CN102293959B (en) | Anticancer traditional Chinese medicine and preparation method thereof | |
| CN104829567B (en) | Compounds, containing its pharmaceutical composition and its preparation method and application | |
| CN1989984B (en) | Chuanxiong rhizome effective ingredient, preparing method, preparation and use thereof | |
| CN101152202B (en) | Pharmaceutical composition for treating respiratory diseases and preparation method thereof | |
| CN101623325B (en) | Ziziphora clinopodioides Lam. total flavonoid extract and production method thereof and application thereof in cardiovascular drug | |
| CN102188459A (en) | Brucea javanica total terpenoid extractive, and preparation method and application thereof | |
| CN101375842A (en) | Application of lignan of biphenyl cyclooctene series in preparing anti-hepatitis B virus medicament | |
| CN105770099A (en) | Externally applied traditional Chinese medicine for treating tinea corporis and cruris and tinea manus and pedis | |
| CN104288169B (en) | A kind of flavonoid glycoside compound and its production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111005 Termination date: 20150804 |
|
| EXPY | Termination of patent right or utility model |